SKF-89626

☆ Save On Wikipedia ↗
SKF-89626
Clinical data
Other namesSKF89626; SKF-89,626; SK&F-89626; SK&F-89,626
Drug classDopamine D1 receptor agonist
ATC code
  • None
Identifiers
  • 4-[(4S)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-4-yl]benzene-1,2-diol
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC13H13NO2S
Molar mass247.31 g·mol−1
3D model (JSmol)
  • C1[C@H](C2=C(CN1)SC=C2)C3=CC(=C(C=C3)O)O
  • InChI=1S/C13H13NO2S/c15-11-2-1-8(5-12(11)16)10-6-14-7-13-9(10)3-4-17-13/h1-5,10,14-16H,6-7H2/t10-/m0/s1
  • Key:QDKUSZZMIFQVPN-JTQLQIEISA-N

SKF-89626 is a highly selective full agonist of the dopamine D1 receptor of the thienopyridine family.[1][2][3][4][5] However, the drug only weakly crosses the blood–brain barrier.[3] SKF-89615 and SKF-89626 were the first selective and full-efficacy dopamine D1 receptor agonists to be discovered.[4] They were first described in the scientific literature by David E. Nichols and colleagues in 1985.[4][6]

See also

References

  1. "Delving into the Latest Updates on SKF-89626 with Synapse". Synapse. 28 March 2026. Retrieved 9 April 2026.
  2. O'Boyle KM, Waddington JL (December 1987). "New substituted 1-phenyl-3-benzazepine analogues of SK&F 38393 and N-methyl-thienopyridine analogues of dihydroxynomifensine with selective affinity for the D-1 dopamine receptor in human post-mortem brain". Neuropharmacology. 26 (12): 1807–1810. doi:10.1016/0028-3908(87)90139-0. PMID 3501846.
  3. Clark D, White FJ (1987). "D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications". Synapse. 1 (4): 347–388. doi:10.1002/syn.890010408. PMID 2971273. SKF 89626 and SKF 89615 (Theux et al., 1985) are two further derivatives of SKF 38393 which exhibit a marked selectivity for D1 receptors. These compounds have been classed as full agonists at D1 receptors, in contrast to the partial agonist profile of SKF 38393 and fenoldoPam, since they stimulate adenylate cyclase activity to the same extent as DA. SKF 89626 only weakly penetrates the blood-brain barrier (Andersen et al., 1987).
  4. Andersen PH, Nielsen EB, Scheel-Krüger J, Jansen JA, Hohlweg R (June 1987). "Thienopyridine derivatives identified as the first selective, full efficacy, dopamine D1 receptor agonists". European Journal of Pharmacology. 137 (2–3): 291–292. doi:10.1016/0014-2999(87)90240-8. PMID 2956116.
  5. Salmi P, Isacson R, Kull B (2004). "Dihydrexidine--the first full dopamine D1 receptor agonist". CNS Drug Reviews. 10 (3): 230–242. doi:10.1111/j.1527-3458.2004.tb00024.x. PMC 6741759. PMID 15492773. Two earlier described agonists (not of the benzazepine family), SKF 89626 and CY 208-243, were introduced as full dopamine D1 receptor agonists but their status as full agonists was later questioned (29,59).
  6. Truex LL, Foreman MM, Riggs RM, Nichols DE (1985). "Effects of modifications of the 4-(3, 4-dihydroxyphenyl)-1, 2, 3, 4-tetrahydroisoquinoline structure on dopamine sensitive rat retinal adenylate cyclase activity". Society for Neuroscience Abstracts. 11: 315.